ArticleGut2022
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
Article in Gut, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05782465 (Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia), which is not on this map. Cited by 64 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)
Who cites it
64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Pooled it
- ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions.The American journal of gastroenterology · 2025Guideline
- Quality indicators for upper GI endoscopy.Gastrointestinal endoscopy · 2025Guideline
- The role of the endoscopic grading of gastric intestinal metaplasia in assessing gastric cancer risk: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Diagnosing and grading gastric atrophy and intestinal metaplasia using semi-supervised deep learning on pathological images: development and validation study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Trial
- Endoscopic grading of gastric intestinal metaplasia and microvascular pattern for assessing gastric cancer risk: a prospective study.Annals of medicine · 2026Article
- AI Revolution in Upper GI: Endoscopic Diagnosis of Gastric Cancers and Premalignant Neoplasms.Diseases (Basel, Switzerland) · 2026Review
- A TRIM15-CDX2 loop drives bile acid-induced gastric intestinal metaplasia.Molecular medicine (Cambridge, Mass.) · 2026Article
- Reproducible Topographic Phenotypes and Three-Phase Anatomical Evolution of Gastric Intestinal Metaplasia.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- OLGA and OLGIM Stages for Predicting Metachronous Gastric Neoplasm After Endoscopic Submucosal Dissection in Patients With Early Gastric Cancer Without a CurrentJournal of gastric cancer · 2026Article
- The Predictive Value of the EGGIM Score for Extensive and Incomplete Gastric Intestinal Metaplasia: Implications for Biopsy Reduction in Endoscopic Practice.Digestive diseases and sciences · 2026Article
- Gastric intestinal metaplasia: unraveling the multifactorial pathogenesis and advancing risk stratification for gastric cancer prevention.Cellular and molecular life sciences : CMLS · 2026Review
- Dietary Factors Associated With the Progression of Gastric Intestinal Metaplasia: A Multicenter, Prospective Cohort Study in a Western Population.Clinical and translational gastroenterology · 2026Article
- A Nomogram for Predicting Metachronous Gastric Cancer After Endoscopic Submucosal Dissection of Early Gastric Cancer Following SuccessfulJournal of gastric cancer · 2026Article
- Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence.Cancer discovery · 2026Article
- The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus.Histopathology · 2026Article
- Prevalence of anxiety, depression and associated risk factors in gastroenterology outpatients: a multicenter cross-sectional study.BMC gastroenterology · 2026Article
- Boundary-guided VMUNet for atrophic gastritis lesion segmentation in magnifying endoscopy with narrow-band imaging.Frontiers in medicine · 2026Article
- Leveraging Natural Language Processing to Accurately Identify Histologically Confirmed Esophageal and Gastric Premalignant and Malignant Conditions Using a Large-Scale Health-Record Linked Genomic Biobank.Gastro hep advances · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the incidence of gastric cancer (GC) attributed to gastric intestinal metaplasia (IM), and validate the Operative Link on Gastric Intestinal Metaplasia (OLGIM) for targeted endoscopic surveillance in regions with low-intermediate incidence of GC.
methodsA prospective, longitudinal and multicentre study was carried out in Singapore. The study participants comprised 2980 patients undergoing screening gastroscopy with standardised gastric mucosal sampling, from January 2004 and December 2010, with scheduled surveillance endoscopies at year 3 and 5. Participants were also matched against the National Registry of Diseases Office for missed diagnoses of early gastric neoplasia (EGN).
resultsThere were 21 participants diagnosed with EGN. IM was a significant risk factor for EGN (adjusted-HR 5.36; 95% CI 1.51 to 19.0; p<0.01). The age-adjusted EGN incidence rates for patients with and without IM were 133.9 and 12.5 per 100 000 person-years. Participants with OLGIM stages III-IV were at greatest risk (adjusted-HR 20.7; 95% CI 5.04 to 85.6; p<0.01). More than half of the EGNs (n=4/7) attributed to baseline OLGIM III-IV developed within 2 years (range: 12.7-44.8 months). Serum trefoil factor 3 distinguishes (Area Under the Receiver Operating Characteristics 0.749) patients with OLGIM III-IV if they are negative for
conclusionsWe suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III-IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.